Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7421424 | 1.00 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL18911819 | 0.86 | — | — | |
| SCHEMBL21936287 | 0.86 | — | — | |
| SCHEMBL18911847 | 0.86 | — | — | |
| SCHEMBL23519972 | 0.86 | — | — | |
| SCHEMBL24900919 | 0.86 | — | — | |
| SCHEMBL18912001 | 0.86 | — | — | |
| SCHEMBL23519793 | 0.86 | — | — | |
| SCHEMBL18912022 | 0.86 | — | — | |
| SCHEMBL7957618 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6156752-A | Optically active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC (US) | 2000-12-05 | — | — | US | claimed |
| EP-0899261-A1 | Optical active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 1999-03-03 | — | — | EP | claimed |
| EP-0566609-A1 | AZABICYDIC AND AZATRICYDIC DERIVATIVES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1993-10-27 | — | — | EP | claimed |
| EP-2523562-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | ASTRAEA THERAPEUTICS LLC (US) | 2019-01-02 | — | — | EP | disclosed |
| US-9670198-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9062042-B2 | Nicotinic acetylcholine receptor modulators | ASTRAEA THERAPEUTICS, LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150148541-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Astraea Therapeutics (US) | 2015-05-28 | — | — | US | disclosed |
| US-6156752-A | Optically active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0899261-A1 | Optical active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 1999-03-03 | — | — | EP | disclosed |
| WO-1992012149-A1 | AZABICYDIC AND AZATRICYDIC DERIVATIVES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148541-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | CHRNA3, CHRNA4, CHRNA2 | CHRM2 24/4885CHRM4 17/4885CHRM1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.